Navigation Links
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Date:12/1/2008

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr. Andrew Roberts at the Royal Melbourne Hospital and Dr. John Seymour at the Peter MacCallum Cancer Centre.

"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518's strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF."

CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated i
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
11. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:7/22/2014)... Bar, CA (PRWEB) July 22, 2014 ... leading provider of enterprise Time and Attendance / ... in Iowa, a NOVAtime 3000 customer since 2007, ... self-hosted, licensed version of NOVAtime’s state-of-the-art, web-based time ... Lutheran Services in Iowa (LSI) is a human ...
(Date:7/22/2014)... Orem, UT (PRWEB) July 22, 2014 Most people ... first is a weak appetite and the second is a fast ... CB-1 Weight Gainer provides ways to help fight these ... lack of appetite. There are people out there who just can’t ... take bites and then they are full. The cause of this ...
(Date:7/21/2014)... designed to target and kill cancer cells could boost ... and help avoid amputation, a new study reports. , ... the effectiveness of a genetically engineered version of the ... use of the virus alongside isolated limb perfusion chemotherapy ... arm or leg as an alternative to amputation ...
(Date:7/21/2014)... July 22, 2014 iFitDress.com, a famous ... women, has announced its exclusive collection of 2014 ... a promotion for its brand new gowns. , iFitDress.com ... the current market. Its sales boomed in the recent ... products, but also because of the amicable services offered ...
(Date:7/21/2014)... July 21, 2014 The League of ... 1199SEIU United Healthcare Workers East (“1199SEIU”) today announced a ... issues facing healthcare providers and their employees. , ... require ratification by League and 1199SEIU members, employee wages ... addition, all existing worker benefits, including healthcare coverage with ...
Breaking Medicine News(10 mins):Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 3
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: